Lucid Diagnostics
LUCD
32 hedge funds and large institutions have $9.09M invested in Lucid Diagnostics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 10 closing their positions.
1.64% less ownership
Funds ownership: 8.99% → 7.35% (-1.6%)
9% less funds holding
Funds holding: 35 → 32 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
49% less capital invested
Capital invested by funds: $17.8M → $9.09M (-$8.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$676K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$233K |
| 3 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$228K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$146K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$132K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LM
Luminus Management
Houston,
Texas
|
-$1.84M |
| 2 |
CC
Covalis Capital
London,
United Kingdom
|
-$722K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$437K |
| 4 |
Millennium Management
New York
|
-$351K |
| 5 |
CF
Cantor Fitzgerald
New York
|
-$305K |
LUCD Hedge Fund Activity: Q1 2022 in Review
32 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Lucid Diagnostics (LUCD) for Q1 2022, worth a combined $9.09M — down 49% from $17.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LUCD and 7 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 7 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $676K. The largest seller was Luminus Management, cutting an estimated $1.84M.
- 32 institutional investors held Lucid Diagnostics (LUCD) as of Q1 2022, down from 35 in Q4 2021.
- Funds reported $9.09M of Lucid Diagnostics stock for Q1 2022, down 49% quarter-over-quarter.
- 7 funds opened new Lucid Diagnostics positions in Q1 2022 and 10 closed out, a net change of -3 holders.
- The largest Lucid Diagnostics buyer in Q1 2022 was Bridgeway Capital Management, an estimated $676K added.
- The largest Lucid Diagnostics seller in Q1 2022 was Luminus Management, an estimated $1.84M sold.
Based on aggregated 13F filings for Q1 2022.